Next-Generation Sequencing (NGS) is increasingly being used for HLA typing. Several NSG-based protocols have recently being developed by various companies by building their respective NGS platforms. The report 鈥淕lobal Transplant Diagnostic 麻豆原创 (HLA Typing - Molecular Assays and Non-Molecular Assays; Product Type - Reagents & Consumables, Instruments & Software & Services) 麻豆原创 Outlook 2024鈥� provides information on the current scenario, market outlook of the global transplant diagnostic. The market is segmented along types of HLA Typing and Product type. Detailed analysis of these segments are provided in the report. The market is further analyzed with detailed market outlook for global as well as regional markets such as North America, Europe and Asia Pacific. 麻豆原创 outlook for overall market as well as for various segments for aforementioned regions has been provided for the period 2018-24.
The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities in global transplant diagnostic market. The report has been segmented as following:-
麻豆原创 Segments
鈥� HLA Typing 鈥� Molecular Assays & Non-Molecular Assays
鈥� Product Type - Reagents & Consumables, Instruments & Software & Services
Geographical Coverage
鈥� North America - The US
鈥� Europe - Italy
鈥� Asia Pacific
Companies Coverage
鈥� Thermo Fisher Scientific Inc.
鈥� F.Hoffman-La Roche Ltd.,
鈥� Abbott Laboratories Inc.
鈥� Qiagen N.V.
鈥� Immucor Inc.
鈥�
Transplantation refers to the process of replacing damaged or missing organs from donor site. In order to determine tissue compatibility between potential donor and recipient, Human leukocyte diagnostic (HLA) testing is performed. Human leukocyte antigens are basically histocompatibility complex found on cell surface that are used as markers by immune system to recognize cells which belongs to the body. HLA typing maximizes the chances of graft survival while minimizing serious immunologic transplant complications. These tests are performed using various assays- Molecular assays (Serology and Mixed Lymphocyte Culture (MLC) and Non-molecular assays (Polymerase Chain Reaction and Next Generation Sequencing).
Global transplant diagnostic market is driven by rising demand for organ transplants, increasing geriatric population, prevalence of chronic diseases and various favorable government initiatives. However, factors such as organ shortage for transplant, limited medical reimbursement, lack of awareness and stringent regulatory norms are restraining growth of the market.
The report 鈥淕lobal Transplant Diagnostic 麻豆原创 (HLA Typing - Molecular Assays and Non-Molecular Assays; Product Type - Reagents & Consumables, Instruments & Software & Services) 麻豆原创 Outlook 2024鈥� provides information on the current scenario, market outlook of the global transplant diagnostic. The market is segmented along types of HLA Typing and Product type. Detailed analysis of these segments are provided in the report. Geographically, the market is segment along North America, Europe and Asia Pacific region. Future forecasts of transplant diagnostic market overall and across various sub-segments has been provided till 2024, for all the geographies. Furthermore, major industry players have been prudently analyzed in the competitive landscape section of the report in order to provide key comparative insights.
Major industry players operating in the global transplant diagnostic market includes Thermo Fisher Scientific Inc., F.Hoffman-La Roche Ltd., Abbott Laboratories Inc., Qiagen N.V., Immucor Inc., among others. These players are profiled herein based on attributes such as business overview, product segments and financial analysis. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global as well as regional transplant diagnostic market.
1. Executive Summary
2. Research Methodology
3. Transplant Diagnostic
3.1 Overview
3.2 Organ Transplant
3.3 HLA Typing
3.3.1 Overview
3.3.2 Classification
3.3.2.1 Serology
3.3.2.2 Mixed Lymphocyte Culture (MLC)
3.3.2.3 Polymerase Chain Reaction (PCR)
3.3.2.4 Sequencing Based
4. 麻豆原创 Analysis
4.1 麻豆原创 Sizing (Actual & Forecasted)
4.2 麻豆原创 Share Analysis
4.2.1 麻豆原创 Share by Product Type
4.2.2 麻豆原创 Share by Technology
4.2.3 麻豆原创 Share by Type of Organ
4.2.4 麻豆原创 Share by Region
5. 麻豆原创 Segmentation
5.1 HLA Typing
5.1.1 Molecular Assays
5.1.2 Non-Molecular Assays
5.2 Product Type
5.2.1 Reagents & Consumables
5.2.2 Instruments
5.2.3 Software & Services
6. Regional Analysis
6.1 North America
6.1.1 麻豆原创 Sizing (Actual & Forecasted)
6.1.2 The US
6.2 Europe
6.2.1 麻豆原创 Sizing (Actual & Forecasted)
6.2.2 Italy
6.3 Asia Pacific
6.3.1 麻豆原创 Sizing (Actual & Forecasted)
7. 麻豆原创 Dynamics
7.1 Industry Trend & Development
7.1.1 Next Generation Sequencing for HLA Typing
7.1.2 Recent Deals
7.1.3 Other Technological Advancements
7.2 Growth Drivers
7.2.1 Rising Demand for Organ Transplants
7.2.2 Increasing Geriatric Population
7.2.3 Prevalence of Chronic Diseases
7.2.4 Government Initiatives
7.3 Challenges
7.3.1 Organ Shortage for Transplant
7.3.2 Limited Medical Reimbursement
7.3.3 Lack of Awareness
7.3.5 Stringent Regulations
8. Competitive Landscape
9. Company Profiles
9.1 Thermo Fisher Scientific Inc.
9.2 F. Hoffman-La Roche Ltd.
9.3 Abbott Laboratories Inc.
9.4 Qiagen N.V.
9.5 Immucor Inc.
List of Tables
Table 1: Comparison of HLA Typing Technique
Table 2: Analysis of Various HLA Typing Techniques
Table 3: comparison of HLA Typing Techniques
Table 4: Recent Deals in Transplant Diagnostic 麻豆原创
List of Figures
Figure 1: Rockville Research 鈥� Research Methodology
Figure 2: Gene Map of HLA Typing
Figure 3: HLA Typing Classification
Figure 4: Global Transplant Diagnostic 麻豆原创 Size by Value, 2016-24E (US$ Billions)
Figure 5: Global Transplant Diagnostic 麻豆原创 Share by Product Type (2018E)
Figure 6: Global Transplant Diagnostic 麻豆原创 Share by Technology (2018E)
Figure 7: Global Transplantation Diagnostic 麻豆原创 Share by Type of Organ (2017)
Figure 8: Global Transplant Diagnostic 麻豆原创 Share by Region (2018)
Figure 9: Global HLA Typing 麻豆原创 Size by Value, 2015-24E (US$ Millions)
Figure 10: Global HLA Typing-Molecular Assays 麻豆原创 Size by Value, 2015-24E (US$ Millions)
Figure 11: Global HLA Typing- Non Molecular Assays 麻豆原创 Size by Value, 2015-24E (US$ Millions)
Figure 12: Global Transplant Diagnostic Products 鈥� Reagents & Consumables 麻豆原创 Size by Value, 2016-24E (US$ Millions)
Figure 13: Global Transplant Diagnostic Products 鈥� Instruments 麻豆原创 Size by Value, 2016-24E (US$ Millions)
Figure 14: Global Transplant Diagnostic Products 鈥� Software & Services 麻豆原创 Size by Value, 2016-24E (US$ Millions)
Figure 15: North America Transplant Diagnostic 麻豆原创 Size by Value, 2015-24E (US$ Millions)
Figure 16: The US Transplant Diagnostic 麻豆原创 Size by Value, 2014-24E (US$ Millions)
Figure 17: The US Transplant Diagnostic 麻豆原创 Share by Technology (2018)
Figure 18: The US Transplant Diagnostic Molecular Assay 麻豆原创 Size by Value, 2014-24E (US$ Millions)
Figure 19: The US Transplant Diagnostic Non-Molecular Assay 麻豆原创 Size by Value, 2014-24E (US$ Millions)
Figure 20: Europe Transplant Diagnostic 麻豆原创 Size by Value, 2015-24E (US$ Millions)
Figure 21: Italy Transplant Diagnostic 麻豆原创 Size by Value, 2014-24E (US$ Millions)
Figure 22: Asia Pacific Transplant Diagnostic 麻豆原创 Size by Value, 2015-24E (US$ Millions)
Figure 23: Global Organ Transplants Demand by Region, 2011-17 (Units)
Figure 24: The US Organ Transplant Data, 2003-2015
Figure 25: Transplant Procedure by Age (2017)
Figure 26: Global Ageing (Aged above 60 years) Population, 2010-18E (Millions)
Figure 27: Global Chronic Disease Incidences, 2012-18 (Millions)
Figure 28: Global HLA Testing 麻豆原创 Players 鈥� Industry Presence
Figure 29: Global Transplant Diagnostic 麻豆原创 Players Financial Analysis (2017)
Figure 30: Thermo Fisher Scientific Inc. Revenue by Business Segment (FY2017)
Figure 31: Thermo Fisher Scientific Inc. Specialty Diagnostic Revenue by Segment (FY2017)
Figure 32: Thermo Fisher Scientific Inc. Net Sales, FY2013-FY2017 (US$ Billions)
Figure 33: F. Hoffman-La Roche Ltd. Revenue by Business Segment (FY2017)
Figure 34: F. Hoffman-La Roche Ltd. Net Sales, FY2012-FY2017 (US$ Billions)
Figure 35: Abbott Laboratories Inc. Revenue by Business Segment (FY2017)
Figure 36: Abbott Laboratories Inc. Net Sales, FY2013-FY2017 (US$ Billions)
Figure 37: Qiagen N.V. Revenue by Business Segment (FY2017)
Figure 38: Qiagen N.V. Net Sales, FY2012-FY2017 (US$ Billion)
Figure 39: Immucor Inc. Revenue by Business Segment (FY2017)
Figure 40: Immucor Inc. Net Sales, FY2012-FY2017 (US$ Millions)
Thermo Fisher Scientific Inc., F.Hoffman-La Roche Ltd., Abbott Laboratories Inc., Qiagen N.V., Immucor Inc.
听
听
*If Applicable.
